Literature DB >> 29067586

Psoriatic arthritis: is it time to treat-to-target or target to treat?

Ennio Lubrano1, Fabio Massimo Perrotta2.   

Abstract

Treat-to-target recommendations provide physicians a useful strategy to reduce the probability of disease progression and in general to manage PsA patients. However, it could be difficult to apply in real life, since PsA is a very heterogeneous disease with different manifestations to be treated. In fact, depending on the patient's expectation, some aspects of the disease could be prominent or not, beyond the mere achievement of the target of remission or low-disease activity. In this context, the concept of a "target to treat" strategy should be taken in to account.

Entities:  

Keywords:  Outcome; Psoriatic arthritis; Remission; Treat-to-target

Mesh:

Substances:

Year:  2017        PMID: 29067586     DOI: 10.1007/s10067-017-3885-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  21 in total

Review 1.  Updated guidelines for the management of axial disease in psoriatic arthritis.

Authors:  Peter Nash; Ennio Lubrano; Alberto Cauli; William J Taylor; Ignazio Olivieri; Dafna D Gladman
Journal:  J Rheumatol       Date:  2014-11       Impact factor: 4.666

2.  Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment.

Authors:  L C Coates; J Fransen; P S Helliwell
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

3.  Combination therapy with ciclosporin and etanercept in patients with psoriatic arthritis.

Authors:  Salvatore D'Angelo; Maria Stefania Cutro; Ennio Lubrano; Pietro Leccese; Gianna Angela Mennillo; Nicola Ferrara; Ignazio Olivieri
Journal:  Ann Rheum Dis       Date:  2009-08-09       Impact factor: 19.103

Review 4.  Psoriatic Arthritis.

Authors:  Christopher T Ritchlin; Robert A Colbert; Dafna D Gladman
Journal:  N Engl J Med       Date:  2017-03-09       Impact factor: 91.245

5.  Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data.

Authors:  Laura C Coates; Philip S Helliwell
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-07       Impact factor: 4.794

6.  Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study.

Authors:  Fabio Massimo Perrotta; Ennio Lubrano
Journal:  Postgrad Med       Date:  2016-08-16       Impact factor: 3.840

7.  Patients with Psoriatic Arthritis Fulfilling the Minimal Disease Activity Criteria Do Not Have Swollen and Tender Joints, but Have Active Skin.

Authors:  Josefina Marin; María Laura Acosta Felquer; Leandro Ferreyra Garrot; Santiago Ruta; Javier Rosa; Enrique R Soriano
Journal:  J Rheumatol       Date:  2016-03-01       Impact factor: 4.666

8.  Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score.

Authors:  Monika M Schoels; Daniel Aletaha; Farideh Alasti; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2015-08-12       Impact factor: 19.103

9.  Defining Low Disease Activity States in Psoriatic Arthritis using Novel Composite Disease Instruments.

Authors:  Laura C Coates; Philip S Helliwell
Journal:  J Rheumatol       Date:  2015-12-15       Impact factor: 4.666

Review 10.  Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.

Authors:  Josef S Smolen; Ferdinand C Breedveld; Gerd R Burmester; Vivian Bykerk; Maxime Dougados; Paul Emery; Tore K Kvien; M Victoria Navarro-Compán; Susan Oliver; Monika Schoels; Marieke Scholte-Voshaar; Tanja Stamm; Michaela Stoffer; Tsutomu Takeuchi; Daniel Aletaha; Jose Louis Andreu; Martin Aringer; Martin Bergman; Neil Betteridge; Hans Bijlsma; Harald Burkhardt; Mario Cardiel; Bernard Combe; Patrick Durez; Joao Eurico Fonseca; Alan Gibofsky; Juan J Gomez-Reino; Winfried Graninger; Pekka Hannonen; Boulos Haraoui; Marios Kouloumas; Robert Landewe; Emilio Martin-Mola; Peter Nash; Mikkel Ostergaard; Andrew Östör; Pam Richards; Tuulikki Sokka-Isler; Carter Thorne; Athanasios G Tzioufas; Ronald van Vollenhoven; Martinus de Wit; Desirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2015-05-12       Impact factor: 19.103

View more
  3 in total

Review 1.  Consensus-based recommendations on the diagnosis, referral and clinical management of patients with psoriatic arthritis.

Authors:  Hanan Al Rayes; Mansour Alazmi; Suzan Attar; Khaled Alderaan; Mushabab Alghamdi; Nayef Alghanim; Ahmed Alhazmi; Nadeer Alkhadhrawi; Mohammad Almohideb; Zeyad Alzahrani; Mohamed Bedaiwi; Hussein Halabi
Journal:  Rheumatol Int       Date:  2021-10-30       Impact factor: 2.631

Review 2.  Role of comorbidities in spondyloarthritis including psoriatic arthritis.

Authors:  Silvia Scriffignano; Fabio Massimo Perrotta; Antonia De Socio; Ennio Lubrano
Journal:  Clin Rheumatol       Date:  2018-10-18       Impact factor: 2.980

3.  Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices.

Authors:  Ennio Lubrano; Silvia Scriffignano; Ana Belen Azuaga; Julio Ramirez; Juan D Cañete; Fabio Massimo Perrotta
Journal:  RMD Open       Date:  2020-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.